PSM retrospective TriNetX database analysis of 1,379 severe COVID-19 patients requiring respiratory support, showing lower mortality with aspirin (not reaching statistical significance) and famotidine, and improved results from the combination of both.
Mura et al., 3/31/2021, retrospective, database analysis, multiple countries, multiple regions, preprint, 6 authors.
risk of death, 20.3% lower, RR 0.80, p = 0.001, treatment 527, control 527, odds ratio converted to relative risk, aspirin only, control prevalence approximated with overall prevalence.
risk of death, 37.3% lower, RR 0.63, p < 0.001, treatment 305, control 305, odds ratio converted to relative risk, famotidine and aspirin, control prevalence approximated with overall prevalence.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.